(PresseBox)
(Hamburg/Geesthacht, Germany,
2017-06-01)
Indivumed, a worldwide leading biotechnical company in the field of personalized cancer medicine, and Intermed, a medical trading and logistics company, will join forces in the field of personalized cancer medicine in the future. Intermed, as an affiliated partner company, also performs services for LADR Der Laborverbund Dr. Kramer & Kollegen.
Intermed invests and participates in Indivumed in order to accelerate the expansion of Indivumed’s worldwide leading Cancer Database in Germany and, in addition, to distribute through the physician-managed LADR Laborverbund innovative cancer diagnostic test’s offered by Indivumed’s subsidiary Indivutest GmbH.
Innovative diagnostics and logistical perfection
“As a result of the alliance formed with Intermed, we are very glad to receive logistical support for the expansion of our cancer database and, at the same time, be able to provide Central-European wide highly innovative diagnostic tests for personalized cancer medicine,” says Prof. Dr. med. Hartmut Juhl, founder and CEO of Indivumed GmbH.
Prof. Dr. med. Jan Kramer, owner and managing director of Intermed and of LADR Der Laborverbund Dr. Kramer & Kollegen, emphasizes that “by investing in Indivumed GmbH, we partner with one of the leading companies in the field of personalized medicine.”
Cancer database and liquid biopsy - the key to proper treatment
With the worldwide leading cancer database, Indivumed holds an essential scientific key solution for further development of personalized cancer medicine. This has been demonstrated by Indivumed’s participation in the development of the new, groundbreaking diagnostic field of “Liquid Biopsy“. “We are looking forward to partner with IndivuTest GmbH, making available to patients new, highly innovative diagnostic tests through our LADR laboratory network and the logistical possibilities of Intermed across the nation”, continues Professor Kramer.
About Intermed and LADR Der Laborverbund Dr. Kramer & Kollegen
Intermed is an owner-run, dynamic trading and logistics company with more than 900 employees. For more than 30 years, Intermed has supplied physicians, laboratories and health institutions with medical devices and has set up its own logistics system all over Germany. In addition, Intermed is a partner of the medical supply centers in the LADR Der Laborverbund Dr. Kramer & Kollegen, a laboratory network which, with its medical laboratory supply centers and cooperating laboratory associations, provides more than 20,000 doctors’ practices and more than 350 clinics and hospitals with medical laboratory services.
For further information, please visit www.intermed.de and www.LADR.de
Press release BoxID: 855944 (Indivumed GmbH)
- Indivumed GmbH
- Falkenried 88
- 20251 Hamburg
- http://www.indivumed.com
- Contact person
- Hartmut Juhl
- +49 (40) 413383-0
QrCode
What its a QR code?
Three steps: Scanning of a QR code: Find your way to a press release without typing. Use the QR code on the print version of a press release to get redirected to the corresponding page on PresseBox.
How does scanning a QR code work? Just follow these simple steps.
Everything you need is an internet-enabled mobile phone or smartphone with a built-in camera and a QR code reading software.
QR stands for Quick Response - with one step you can quickly reach a website. QR codes work like bar codes, which you can find on your milk carton, for example. A software decrypts the QR code and directs you to a web page - so you do not even need to know the web address to reach it.
Download and print your digital press kit now
Please send the following information to my email address:
Personalized Cancer Medicine - Indivumed and Intermed to form Strategic Alliance
Indivumed GmbH
INDIVUMED GmbH an ISO certified global oncology research company based in Hamburg, Germany, has established the world's leading Cancer Database and biobank, retaining unique patterns of biomolecules such as RNA, DNA, and proteins as they existed in the human body. This Cancer Database makes possible multi-omics capabilities that will allow for characterization of samples and data, such as whole genome gene expression analysis, expression analysis of cancer relevant proteins, expression analysis of cancer relevant phosphoproteins and bioinformatic solutions for integrating molecular, biological and clinical information.
IndivuTest GmbH is a subsidiary of Indivumed GmbH established in 2002. IndivuTest was spun off in 2012 with the objective of making Indivumed's scientific experiences in tissue analytics available to patients and contribute significantly to the establishment of individual cancer therapies in oncology.
IndivuTest offers innovative diagnostic services, which include genomic analyses of blood samples ("liquid biopsy") and comprehensive analyses of tissue to identify optimally suited drugs and therapies of individualized cancer treatments.
For further information, please visit www.indivumed.com and www.indivutest.com
IndivuTest GmbH is a subsidiary of Indivumed GmbH established in 2002. IndivuTest was spun off in 2012 with the objective of making Indivumed's scientific experiences in tissue analytics available to patients and contribute significantly to the establishment of individual cancer therapies in oncology.
IndivuTest offers innovative diagnostic services, which include genomic analyses of blood samples ("liquid biopsy") and comprehensive analyses of tissue to identify optimally suited drugs and therapies of individualized cancer treatments.
For further information, please visit www.indivumed.com and www.indivutest.com
